Aptose Biosciences (APTO)

Susan Pietropaolo Communications Representative
William Rice Chairman, President and Chief Executive Officer
Gregory Chow Executive Vice President and Chief Financial Officer
Rafael Bejar Senior Vice President and Chief Medical Officer
Gregory Renza RBC Capital Markets
John Newman Canaccord
Emily Bodnar Cantor Fitzgerald
Joe Pantginis H.C. Wainwright
Matt Biegler Oppenheimer
Matthew Cross Alliance Global Partners
Call transcript
Due to licensing restrictions, you must log in to view earnings call transcripts.

Good afternoon. My name is Chris, and I will be your conference operator today. I’d like to welcome everyone to the Aptos Biosciences’ Conference Call for the Third Quarter Ended September 30, 2020. At this time, all participants are in a listen-only mode. After the speakers’ remarks, there will be a question-and-answer session. reminder, call a be As Instructions] this may conference recorded. [Operator Ms. now like would to I introduce Susan Pietropaolo. ahead. go Please

Susan Pietropaolo

Thank you, operational afternoon, I Biosciences. call third Chris. Good ended am to Biosciences the quarter Representative discuss conference Susan Aptose Pietropaolo, financial for XX, and September results Communications the and for XXXX. welcome Aptose to

Marango, and on me and are Chief Mr. Business Chow, Gregory today Officer; CEO; Vice Rafael President Financial G. Bejar, and President William Officer. President, Joining Dr. call Senior Dr. Dr. Officer; Chief Jotin Executive Chief the President Rice, Vice Vice Senior Chairman, Medical

Before to forward-looking statements statements certain I and we include meaning in the laws. proceed, U.S. of would remind everyone within will Canadian like this call securities that

may events and Form performance expectations. I of turn after Biosciences. statements circumstances Report that are now reflect statements they the materially and President, or as speak the XX-K Forward-looking materially and not of Annual law. Aptose unknown CEO Aptose’s All Aptose Chairman, this please by it results and date Dr. of and events Dr. possible the SEC undertakes forward-looking Risk made. reflect and uncertainties, future performance, are to on statements call and will that could actual and recent as over Rice, uncertainties set differ except performance, required involve Rice? known stated the to of call, filings. read revise from assumptions to expressed. that about made Aptose’s update risks or cause SEDAR current call more They this date in forth during regarding and is only those learn from guarantees Factors expectations actual results, these risks, differ most the to achievement To the no obligation

William Rice

XXXX. like to our ended third the quarter I’d call September Thank to everyone for welcome XX, Susan. you,

trial CG-XXX, AML patients clinical and the and other into one studies studies or CLL year are FLTX now clinical leukemia APTO-XXX And patients product operating BTK is our three expanding our with have ongoing where in point, the AML and with substance trial, MYC study inhibitor a initiated we lymphomas. or clinical acute our the with across MDS. myeloid at inhibitor leukemia smoothly the and a non-Hodgkin’s are of We for we chronic drug board, drug third very trial, cancers. our Aptose, with of kinase underway; in with the year, patients programs. We right spectrum our enroll clinical are our for each lymphocytic treating study pace with advancing a recently working now patients in patients challenging, manufacturing, with well and AML, sites the which or accelerating relapsed refractory development two and to has hematologic been with of

position tackling blocking for The to our success. one and third was of quarter agents

only a be XXXX let discuss at programs, our doses to continued pharmacokinetic ASH of begin to few we especially progress and of treat before you one and expect is as higher that weeks three additional remind data. We And execution, we pharmacologic each me clinical to more in away. the short patients generate

relapsed high-level that, we clinical a of said know our news. FLTX blood, we ASH. whom SYK, SICK. or during our and October, most of SYK EGFR SYK, kinases trial marrow suppresses tyrosine the including STAT serious in that spelled first are in a we mutant PD- findings segues cancer and let’s dosing the CSFXR, then So is operative bone AKT, alpha, CG-XXX the select is just oncogenic our refractory and not X AML, the announced or initiation of with as prognosis. wall drug a/b And of and and and way, to clusters and AML, the RAS, very Phase which will recent in that XXX to that we more poor quantitative of CG-XXX ERK, that with carries aim patients remarks keep as today, the will refer kinase Having we qualitative start type FLTX, share inhibits and by BTK, forms spleen pathways. inhibitor In

across agent As and XXX the of gives only known is a you will recall, FLTX broad lymphoid potently which including it malignancies, AML. hematologic and myeloid clinical inhibits both that BTK, spectrum potential the

available safety, patients of remind relapsed trial you very they patients ill. this AML. the a or want dose and as such gilteritinib the that three to standard a again and relapsed but and insufficient multicenter Phase ascending or CG-XXX escalation Phase intolerant of durable before other cohorts X AML is have maximum with are venetoclax not tolerated for the three With And care pharmacodynamics these XXX refractory and I or is have and AML often already patients of are treated before, drugs a/b many refractory to resistance. other patients, with plus joining as such design trial, for recommended relapsed therapies, pharmacokinetics inhibitors, Our refractory but dose FLTX open-label X and determine been in the failed quickly study dose or to with approved leading midostaurin and to or or failed

XXX centers with in the to observations to or efficiently that this enrolled toxicity. totality and additional It XXX pleased of relapsed AML observed place appeared of XX inhibited CLL patient of well that requested mg is separate escalation, kinase AML us our there the relapsed in initiate trial, us levels are allows enrollment. In in dose AML to And safe, mg. allowed care this at a their when FDA a and key patients was remains if the clinical that recent patients traditional three The regional and AML I’m administered trial, open. sites. mg. in clinical XXX. major and in pace trial starting have but call starting starting mg three and news sites, trial led clinical of highly to our of in or mentioned at treating levels work the I we we was patients, XXX, last a plasma dose, XXX to XXX which AML driver the advances, of Aptose patients currently Investigators announced lowest engaged in they caliber, we state including patients clinical are the the sites mg more for to which XXX preclinical and in the patients patients to than the activity, that unmet mice to also the several enroll as a cancer CLL, since as no good tolerated report in for with observed observed the steady slots cohort. achieved Having three mg first and these patients available dose eager the We BID, cures the sites when AML. for dose dosing it with tremendous because refractory XXX need high each plasma FLTX our minimum dosing humans levels dose range dose of we refractory AML with Also dose skip at patients. So at despite dose Five are led now screening two specialty academic levels on plus same in exposure for effectively appropriate. pleased

well us type as has FLTX AML we It And as patients study. holding referred FLTX Some been as to of with FLTX. with the having intention. you of are AML, which our positive have wildtype patients asked now, this specifically, enrolling mutation, AML always ITD patients

AML fragile the In we and believe candidate refractory are benefit patient we very addition, XXX relapsed a for ill, that can AML to and XXX compelling hopeful is the provide patients. population

corporate that the AML ASH we plan up-to-date at trial share will timeframe. during to update a We specific hold

more visit sites trial on AML For please patients, recruiting and clinicaltrials.gov. are information the that clinical

in X to dose malignancies, patients last refractory a/b Now, XXX in with B-cell continue escalation dose XXX non-Hodgkin’s at and the patients XXX current lymphomas of levels. we XXX dose failed and let’s have turn to the escalated who study relapsed or again, of our mg mg Phase intolerant CLL and therapy. are call, we including our to treat patients, Since to and fifth mg level ongoing

are on-target relapsed refractory have for patients. mg exclusively or indications CLL At as XXX the we activity we and only focusing of patients. prior at Importantly, on observed enrolling CLL, dose,

specific that In may if these XXX different that addition In reduces on-target reported we This more and will sites previously, findings to in with we lymphocytosis have are inhibition but to that Again, time ever, such into we and B-cell truly share pill patients, with phenotypic we you understand that pretend and program of more to genotypic scaled-up respond builds, for visit in across of CLL observed additional load phase, allow information and clinicaltrials.gov. expansion the to Depending a that nodal during these developed reductions sub-populations of patients CLL us refractory you accrue that we are additional being as trial are clinical we BTK also the called or and studies, our we trial specific XXX trial. patients require extended fully have level enrolling expansion program capsules XXX with will facilitate induction We process are conjunction hopeful few and update and ASH, patients. automated deep manufacturing provide responses are in-depth to studies place transitioning risk formal will to enroll away. additional the entire for the XXX. during the over patients patients to plan the time the on a step on malignancy properties. dose this on with clinical include may which of is activity just a and weeks introduced ASH. machine escalation CLL please capsules cancer we subgroups

abstracts & that now development CG-XXX carefully OHSU. Oregon study Overall, and believe in our on be and and on Speaking XXX. we’d announced and release, posters available the press City we in X; December ASH execute University at on presented by be will another one CG-XXX poster our of last in distributed press online. details there will research we sales Hope our were of we Health on parallel diligently another partners one two presenting and are milepost week or on programs we week Sunday in and last of represents release the Science ASH, Saturday, the multiple yet the Conference as at and APTO-XXX this

As with biology build that like and indications. potential cancer benefit a array we for believe for we is broad to to-date, potential patients and work our Aptose remain on we shareholders. in XXX of XXX the drug based a no candidate of have value stressed before, singular other confident

it call status you and trial including APTO-XXX, Xb a remind Now, hematologic inhibitor. phase up-to-date me MYC just a is proliferation, in XXX, currently major as cancers. our of bring I’ll you, driver oncogene for candidate a on the to cell clinical of is APTO-XXX, let AML second MDS. MYC the And or cancer

a most one cancer coveted in In have fact, seeking it’s researchers and been MYC in the safe many targets years. of drug

The to For or that or refractory cycle relapsed study XX% XXX our the mg/mX, we’ve report four in enrolled inhibitor. to four doses nobody expansion AML at the patients MYC MYC once protocol, knows what advancing administered radar X designed dose cohorts cohorts. weekly over tolerated Since single interest phase of inhibition be clinical which in as pleased our trial the to then is and/or as last XXX completed being the a from of well-tolerated. dose MDS is in appropriate hitting at to far, been reached. partly a level to over screen, XXX we target, clinical expect call, ascending agent XX our a well. dose thus Despite dose multiple and a have that Phase under of transition XXX MDS. is level with XX-day has and first patients maximum I’m because continues XXX five X increase AML high-risk until dosing quietly

see to doses, investment. clinical as XXX more responses. higher to we our talk sustained about learning we more we We’ll to event valuable began asset and at to be of and proceed MYC you able hope day inhibition XXX is and continue believe We’re to at see ASH. during these four an interesting

please For visit of criteria, interested enrollment learning more you in about trial those the clinicaltrials.gov. specifics and

on quickly corporate Finally, other highlights. touch

of grateful be a to Healthcare and We’re Conferences. Banking part Upcoming recent

full Canaccord and Wainwright, meetings. we presented hosted the Oppenheimer the H.C. quarter, a conferences, one-on-one Genuity, we During cantor or schedule of at

Chief hosting Financial quarter. our be the review for have week, Stifel to also December. in and we’ll to President been one-on-one conference, will in We who be will turn the over the Officer, Sandler Chow, healthcare Vice Executive the invited participating Piper we healthcare and will next meetings conference mr. And call where we results now, early Greg

Gregory Chow

this and the and cash, We to good cash everyone. in million afternoon, approximately of $XXX approximately at compared million ended bill $XX equivalents you, June year. quarter with Thank investments XX

we purposes. resources based into cash cash research activity on attributable surrounding approximately the to activities, company were including provides XXX During September well as to in utilized as quarter, and administrative fund XXX, $X.X company and of operating operations, sufficient on at million XXXX. hand and plan current with development operations, XX, all of general which QX the

costs studies. $X.X $XX.X research $X.XX general for EDGAR quarter, headcounts improving million Moving the had SEDAR. detailed and for on Rice. in which net trial and to million attributable formulations our and quarter. More and for found the call on over clinical loss development the and GMP and expenses quarter costs clinical on administrative XXX our back income quarter were trials, and per will the for manufacturing statement. including and or filings now We for information for XXX, Dr. personnel million trials can the Bill? and to be to revenues supporting $X.X is for were no XXX research turn development XXX expenses activities continuing and clinical the share. manufacturing I

William Rice

could, to operator, Officer as a Thank you, our we us. the call questions, Greg. to introduce we dr. feel you Chief us, of if Jotin the our I’ll also remind open and with Chief everyone Business for first on please question. that Officer. Marango, Medical Bejar, please free Rafael dr. line, the question pose any have


of Thank [Operator Markets. Instructions] from Renza first with Gregory RBC Your question line you. the Capital comes

now open. line is Your

Gregory Renza

you questions. Hey, the good question my some and Congratulations events really, if wanted upcoming ASH just that afternoon, the for on of team. for of I progress set to good start, evening, Bill and able the course, Bill, expectations all taking to is data. and thanks are the natural

in AML I mentioned, Now, just collection can start of acknowledgement data think and you weeks the those just what points those expect be maybe, we maybe to of the we more could will of October, where for some patients us in you the on just start post look enrolling remind be light or trial. certainly speaking meaningful your you. qualitatively, what out just several in Thank but as side, of

William Rice

question. All right. Hey Greg, for us thanks for the joining

collect blocking that we the had approvals. era mentioned I trials patient IRB in and particular, the and the number the active study clinical side, AML AML go Since sites, our to to, we QX. that then speaking more quarter, tackling, to did snapshot up And hopefully, what actually allowed the enrollment, to a than running, in the that definitely into more look third enrolled patient I’m active. team yet, to but sites the of and now a us we’ll time, I on as these had the sufficient population. seeing We give and on the clinical one. directly of we’ve it’s then in that be back between first patients. in So been get have had to very all we bit the put challenge, say you And yes; of it’s data can IND we’re allowed during able we’ve the not patients as to COVID, ready little

the at level. past XXX drug the the But has Of dose these are sick. well tolerated is that and It well been in be very patient mg the to course, tolerated population patients that we level. going hope dose at

beyond we counts. watch see the So of trial. for we not, parameters the equivalent that. that, is And for watch to the or then whether in that hope we determine pharmacokinetic any to will the other that’s the CLL saw CBC first pharmacokinetics, will it we

counts state get remind you two-week off So they wash patients. up also washout, them them, those we sick allowing week be couple are come And typically than during weeks, of levels. at these that or you hopefully, these one first other looking the two. while out, rapidly. patients, that your progress then patients on treating its during trial. get that the drug until we’ll blast steady end of don’t but And Oftentimes the of very hospice, week the very But they go I’ll to you’re to These patients. on reach you’re their as

that we data. I away. we’ll if But So, don’t the and patients stay on truly are patients during these give any time hold those we’re the meaningful patients. to of if hope several time on have reach there to weeks levels these level state benefit period, are in able drug we really see actually to know steady some

now indicate will to time. What time. it at we’ll continue not that month back data operations data. either overpromise at is do collect trials to you have verified that between and will will the able the data I underpromise. then, then then your remind it that clinical I present But the and at the takes don’t a what are want because present we we We collect group, where we’ll you and your through data, be and “verified,” verify to be sites clinical at to least or

AML. So that and preliminary will your discuss that are question. data very but be anything for at that time, we we Hope answers helpful the non-verified

Gregory Renza

and but Thank want I plans just you. how terms to of be Could just at subpopulations. cohorts liberty the the of a respect on CLL your dosing the just XXX turnover get the for to that levels, the cards want understanding thinking I dose to expansion level remind on in thoughts refresh and us certainly cohort course, there? the I about with on a does, mg there, we current heard may just could of in if follow guys and up on think your side, sure us It if you potential Bill commentary and on remind you

William Rice

do Well, XXX to mg safe XXX requires, in dose XX this level. if the level, that protocol, tends to go is Currently, days mg to level determined we’re a mg at the we is have at XXX be ability dose least complete the – of dose dosing. to

escalate to or XXX patients. the We and pharmacokinetics, that level ASH, be these on haven’t show patients lower patients. are XXX during want speak safe information say to then or additional mg, levels that able And on are, and will, are able exposure. whether up, be level of that we we we able to the rising on XXX to be have if get presenting provided we show move are data that the released will hopefully the any is getting to we if level mg have continue everything the particular, we’ll the we as to want up do we to that mg we’ll continuing dose not be to If – increased except these we In XXX we or not. to to mg. we to go to able

look is the for back which if we from if to to XXX, gone reason, turns we cannot XXX, XXX, to we would then out can continuing go turned it XXX, exposures, have we’ve to out be say, reason show we some up As additional would XXX, some phase would get our dose, XXX. If that for recommended to reason, and we’re to go safe. we XXX. to too XXX, down some XXX toxic is we XXX shown X that then

are those possibilities of this all time. correct. at So, That’s

Gregory Renza

Bill. Thanks,

December. Looking the updates forward to in

William Rice

you. Thank


line John from now of Newman open. Canaccord. line your comes question with the The you. Thank is

John Newman

if your and could just Hi here. you to some taking in upcoming question nodal in data remarks, forward my you I guys. the CLL ASH about during comment wondered prepared think Bill, patients. reductions Thanks I talked for looking

elaborate could that you on bit more? if little wondering just a Just

William Rice

the thanks question. John. for Sure,

refer nodal to we So, reductions. these

them them mostly, some reductions, tumor call reductions. nodal Of course, some people

follow So, and these dosing they’re start patient the study, on that they get typically, of the drugs. scan with are their lesions whenever point, they any initial target throughout the at therapy a going comes that the nodes. before they to And lymph identify

it. to don’t refer as careful this And and call reductions because here, it, overplay to we want really them so nodal to going we I’m be either will underplay or internal

than of So, been is, responses. And reductions of yes, not in I patient, nodal reductions asked the formal getting they but one they not in or we’re patients. said were, as repeatedly responses. formal we’ve seen of these level more whether can we say what at If we are any would yet, have have

those of able onto cautious So, been before the These time. our we ever we we of see could there, progress the would they again, out reductions. drugs continue but come not, decreases. a many plateau our continue seen very they they or competitor and response, if patients, have some we’re may that the are if they or relapsed reductions refractory off reach realistic. had who have may thrilled We have level optimism be of to but at all deep trial formal any including drugs to failed patients

adequately and formal that’s very want we’re So, follow point. question reduction why the the you at that in saying, or yes, candid at being but it level Did careful – up? very to did reductions. nodal your not level is of we’ve seen answer this true

John Newman

I to well And both quick FLTX-ITD with one achieve are additional the that or specific mutational for or those looking you mentioned looking the Is looking call to with which me of wildtype. question, study, beginning as at that are with both AML to excuse the include those – there as enroll types you was simply Yes. ratio had that you’re steps? any mutational patients you of

William Rice

about quickly two of drug that well react we’d have, the maybe of who respond in patients believe positive, upfront like the to being patients as we and FLTX-positive what have majority there, and the dose the one, patients this linked like wildtype, and why? know more patients. get to tend as mutation to Well, again, inhibitor. of the cohorts like on We’d minimum. a ITD to wildtype We or FLTX but a to we FLTX very been with early the treat would we’ve wildtype patients, positive can both FLTX. number this FLTX FLTX

Those what And would but you patients the the be most fruit, low-hanging responsive to is. it used be expect FLTX. to ITD really a so would word

multiple each we go, in activity dose So, levels, higher FLTX-positive patients want the dose show And clearly, these but that we and the dose to get escalate get assuming we’re levels. continue able will. on patients, of to we FLTX-positive once we to to as

over patients FLTX of We study and on more the as because take to wildtype get escalate, the transition with this additional we of to be wildtype will patients against drug then too. want continue might dose to levels effective it

John Newman

Yes. Great.

William Rice

you, Thank John.

Gregory Chow

you. Thank


comes And Alethia our next with from line Young the of question Cantor Fitzgerald.

Your line is now open.

Emily Bodnar

Hi. just for Thank This Emily dose process has kind that could think study study you NASH? in potentially that the and helped and patients, you you for CLL do was you question. enroll the taking what Thank have you wondering, CLL my from is so you. besides on you AML by learned the up Alethia. starting mentioned the I of speed far

William Rice

Emily. hi. Hi, we tell Alethia said please

the from levels, what collected So, also from was levels exposure that have that at you patients, the very plasma models. us, animal said, the we for as but learned we important gave starting responses true those we’re in dose, learned? that us that above So, the we or

cured FLTX-positive levels in that animals achieving and dose in they FLTX-ITD AML humans. of So, or exposure AML we’re was mice

humans cells. on those in and plasma, the to other reporter them when The back we we thing the the collect is laboratory bring put

whether can we off plasma, pathways sorts, to were not of wildtype. that or we plasma pathways we; that, the FLTX-ITD, now other SYK, FLTX-positive earlier, and turn FLTX systems to these But in the wildtype all activity these various of was off us reporter we’ve it’s those We the mentioned and able the, that the FLTX I beyond PDGFR-alpha turn ITD ERK, downstream. STAT, fossil able cells have see cell activity to that been able at look to allow

that’s patients, what those an gives level hopefully, effects in those go a see us that overtime. a that patients that we in at begin into can AML is have to can Amgen responses once the then we So and comfort hope we drug

number that terms patients, we disclosed yet In haven’t publicly. of the of

well patients number AML ASH. the disclosing during be as we’ll CLL expected patients as So, of

Emily Bodnar

Okay. Thank you.


Wainwright. Thank from line with question next Joe of our you. And H.C. comes Pantginis the

line Your is open. now

Joe Pantginis

the little evening. you Good for suspect a I further on question. if take range, fall qualitative. quantitative into had my Bill, just wanted commentary the question I the I Hey, might the to not But Thanks the guys. responses taking nodal may.

patients So, describe just within maybe, doses? the period and at many seen responses how I you was curious treatment when if could the were what time for they

William Rice

hear great remind your and Hi, Joe. Dr. a But if the presenting that Bejar up it’s time you won’t information we you the has means data the question. falls he video have that which XX I’d up-to-date you all be to so But the or during at quantitative are November, time. will presentation. month about He have back validate of all on right, to will the did I record presentation a disappointed to you in data, be the that scans. voice has at ASH. to arena. into those

be you’re with additional at any time. that reduction continued X updated X that will have timeframes, around hope on provide those you I November and then into the absolutely the excuse into be presented earlier, me, do not But to we effect, those, on level in and believe and of X data it’s right will levels we area, but that time. he just December you, either responses Again, said we we over presentation, exposure information of But we’ll no ASH. start that for data the at that what on guarantee. able So, quantitative this asking. Joe may deliver for to, provide actually, to data you be to seeing And or that if December you get – getting we able X of once presentation some under-promise as some November amount – as will timeframes the believe which those I don’t yet can see want the you the the on patients of as formal and they’re the thank time response. there, right much But at have, it’s

Joe Pantginis

a understood. Thanks totally guys. Now, lot,

William Rice



the Matt next our from question And Thanks. Biegler line of Oppenheimer. comes with

open. Your line now is

Matt Biegler

Tell, seeing precluding as questions. objective classify my horse counts the ability here, you’re to to fact at nodal sorry is taking or for here. thanks a all just nodal responses not the but blood that a your responses guys. responses as lymphocytosis on Hey, dead beat the factor

William Rice

as give and Well, give the on-target exposures that or BTK us achieved limit the said levels lymphocytosis. – dose No. us we’ve inhibit that we’ve before,

So tell get tells whether other responses going you’re we’re pathways hitting But target doesn’t the patient. in too. that to not a and that or us you

then and and Sometimes, you get then lymphocytosis you’ll get responses. it diminish, will

without responses get you’ll lymphocytosis. Sometimes,

Sometimes, the you lymphocytosis responses. will not drop and occur and it get down will

to of is it your the drug. patient specific each So, response

And no of cut expect. that so there’s we could type dry and pattern

So, little expand perhaps to you a bit could Dr. give on thoughts. that his Bejar

Rafael Bejar


a they’re could that are I it response, count, a different in is limiting ones that it organomegaly, the formal different lymphocyte can for you patient. before for be That need aspects IWCLO that patients the not you to have patient may it the it PR and had a necessarily order and patients right. criteria, following met, has several same say be CLL there be way think or different the could the each node the size, it be there’s be exactly said could to for aspects lymph

William Rice

answers that Thank you, Dr. Matt, your Bejar. question?

Matt Biegler

lymphocytosis but sounds a little confused, different wasn’t and sure helpful. seen was a it was just I Yes. That’s I’ve studies because different. than with it’s PR was nodal like some that report a I I very if response, –

William Rice

nodal the and continuation size, be reduction Well, nodal that would of PR in lymphocytosis. you of XX% with a even get the a

Matt Biegler

first it. trial? can And response you it. Okay. when the just assessment Got kick the quickly, is marrow in Got AML from

William Rice

what depending out make bit months, will a in probably decision. We the you ASH. to get more see will it little No. can that physician the couple we of Typically, patient, a speak to on a be when

If cycles you’re two months typically say let’s several out, out.

on seeing patient would If want then that something But anything then Bejar you’re to to really bone judgment they might they to also that in make like not a they’re time. if want Dr. may want they wait. that opine call, that. marrow seeing a at

Rafael Bejar

two between add some average cycles response. I the is studies FLTX these to three inhibitor therapies. and median how time for and a it would other just was long of time experience studies of The see from

might respond. So, see and who you to two are expect months respond, three going most who patients be of when to therapy

William Rice

Thank you.

Matt Biegler

Got it. guys. Thanks,

Looking ASH. forward to

William Rice

Okay. you. to seeing Look forward

Matt Biegler

you. Thank


Global the Our from comes Instructions] Alliance Partners. Cross line [Operator Matthew with next of question

is open. line Your now

Matthew Cross

questions Hey, of a me. clarifications for Really, couple on just update for a my and guys. end. Thanks taking couple the of pre-ASH from

FLTX least back in the I think to I some regarding the looking kinds of at to for having AML maybe see. focus John’s at you patients wanted and mentioned in enrolling on should question ITD like some what wild and there subtypes beyond may that some thinking I wildtype populations? we that, include or targets those you’d FLTX-ITD. who patients, going or versus to would confirm, screening that of of the patients, status around we trial some of or just be exclude, rare more are be type this TKD these a to guess, kinds looking as – also Does you’re positive as FLTX some about meet

William Rice

positive. FLTX say the the into if to Hi, People drill typically, you details. Matt. to are Typically, referring they FLTX-ITD. Great, down

patients So, variety out either I many patients treated various and a or and inhibitors, are venetoclax, And going these to would those FLTX-ITD mutations. study. with drugs the all is going have have other break what it to so have FLTX on we of there drugs, out FLTX-TKD, been some we’re of like combinations. to person like They find say to

have depends the some past. that drugs You the but not ITD They TKD that TKD, upon had in mutations. or the have ITD. the sequence the might of may It they’ve find

RAS trial, the we IDHX. a mutations, variety period this that So, would PPTX these of have see to of those over mutations, patients, love

the get least a be the of or initially, can in maybe are here doses, variety that above that be likely Once types, get FLTX are higher that doses there. might up positive lower FLTX-ITD. XXX. so The to have with some these into mutations patients at FLTX to or other enough? especially with activity we sure most So, at to that want the but ITD we Fair see make the mutation the XXX drug, to the able along point, a patients we we all the patients at to have able various of to response

Matthew Cross

steer those past had perfect echoed on. at in these kind I higher you XXX looking side abstract, the at wanting is Then Waldenstrom’s the remarks, of correcting level, towards you’ve an a levels, trial CLL, your exclusively the patient me to B-cell particular focus enough. I and know to patient come dose that mentioned, at least the guess but at dated, investigators this Thanks and milligram in or on like, nomenclature for in and patients Fair it the which you’d Yes. know, looked in – MCL on sense. the dose looking makes on obviously I

thinking and in that that sites I a for something dose enrollment XXX specifically form or think I of guess forward? amendment protocol those be more focus, would of the that criteria a going CLL to be the preference around might about full these just communicated really mg maybe, So, group cohorts

William Rice

question. drill down Another

blocking the and So about quarter. tackling. yes, we’re It talking not third was

one So, the made. of this we decisions is

patients responses, drug lymphomas of it other most we’re real determine it’s the we’re able of patients that we a it reached actually some makes we be through nodal exclusively up as the different and why. mg, site understand have what dose a level, it’s and there. decision also want of mg getting always form level higher that CLL made them hear, of what we’ve point, but to XXX to patients, as dose on this higher them there, And that they XXX patients doing, and the to they hopefully, preference from get So, on are because give to of the possible, that likely patients that not these on go they’re level communicated to understanding are to to they keep forward. you dose of going more limps, And reductions variety we to way at your not or beyond, did once for I CLLs, know types of that to but quickly a different the not that all going up drug. variety a the levels whether try population. in these accepted and types developable focus dose developable SLLs, a can But so patient this types as word, we all activity to back at then has

where the taking slow did the right that’s lymphomas it now, the are not – we that anymore. we’re So accrual, and because

stabilized And competitor provide we CLL we’re to them also observed patients time lot patients over then very that benefit. that We’re other these failing But get drugs out the are focusing to happy hopeful drugs. get there, the on these are hopefully, to we’re show a of we to able patients. are that can and them sick patients that be

Matthew Cross

Thank answers month. always to great. full the looking details good as Okay, you for getting next me and to forward having integrity about

William Rice

Thanks Absolutely. Matt. so much,

Matthew Cross

you. Thank


now at And I’m Rice back showing the to would on to Dr. time. closing the turn any further for not this line phone questions call remarks. any like I

William Rice

work, in to trials proud are joining All for the family, right. Well, people, and at all and I our the the clinical organization, these who participated investigators, very everyone, important importantly, to you here we thank to of We thank and progress, support forward I’m and data all whether analysts, of everyone. digging the on good really related our their patients us this clinical these our you who a I the want prize of the have top-notch who’s our afternoon. for the of it’s coming shareholders were evening and today and to trials manufacturing. keeping or want say into a and look all you sites; of and appreciate


conference that gentlemen, today’s Ladies and call. concludes

have wonderful You Everyone, disconnect. day. may a